Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover
Read More(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover
Read More(By Judith Graham for KFF Health News) The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and
Read More(Source – news.va.gov) A Marine Corps Veteran got an infusion of hope this week when he became the second patient
Read More(By Alex Montero, Grace Sparks, Ashley Kirzinger, Isabelle Valdes, and Liz Hamel for Kaiser Family Foundation Published: Aug 04, 2023)
Read More(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely
Read More(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave
Read More(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following
Read More(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval
Read More(Source – www.cms.gov) The Centers for Medicare & Medicaid Services (CMS) is committed to fostering innovation while ensuring that people
Read More(By Arthur Allen for KFF Health News) On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant
Read More